Two Sigma Advisers
ABCL icon

Two Sigma Advisers’s AbCellera Biologics ABCL Stock Holding History

Two Sigma Advisers’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,878,000
Closed -$16.7M – 8
2025
Q4 		$16.7M Buy
4,878,000
+78,100
+2% +$349K 0.03% 396
2025
Q3 		$24.1M Buy
4,799,900
+729,600
+18% +$3.22M 0.05% 280
2025
Q2 		$14M Buy
4,070,300
+1,425,500
+54% +$3.55M 0.03% 421
2025
Q1 		$5.9M Buy
2,644,800
+36,400
+1% +$104K 0.01% 720
2024
Q4 		$7.64M Buy
2,608,400
+430,800
+20% +$1.2M 0.02% 559
2024
Q3 		$5.66M Buy
2,177,600
+412,800
+23% +$1.14M 0.01% 669
2024
Q2 		$5.22M Buy
1,764,800
+7,200
+0.4% +$27.2K 0.01% 740
2024
Q1 		$7.96M Buy
1,757,600
+764,300
+77% +$3.9M 0.02% 607
2023
Q4 		$5.67M Buy
993,300
+290,400
+41% +$1.35M 0.01% 749
2023
Q3 		$3.23M Buy
702,900
+112,600
+19% +$685K 0.01% 938
2023
Q2 		$3.81M Buy
590,300
+49,900
+9% +$341K 0.01% 880
2023
Q1 		$4.07M Sell
540,400
-88,400
-14% -$803K 0.01% 897
2022
Q4 		$6.37M Buy
628,800
+161,100
+34% +$1.86M 0.02% 680
2022
Q3 		$4.63M Buy
467,700
+420,400
+889% +$4.61M 0.01% 771
2022
Q2 		$504K Buy
47,300
+22,900
+94% +$194K ﹤0.01% 1919
2022
Q1 		$238K Buy
+24,400
New +$231K ﹤0.01% 2327
2021
Q2 		– Sell
-20,800
Closed -$706K – 2419
2021
Q1 		$706K Buy
+20,800
New +$829K ﹤0.01% 1845

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Advisers's ABCL Position: Q1 2026 in Review

Two Sigma Advisers sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 4,878,000 shares — an estimated $16.7M sold.

Two Sigma Advisers first reported a position in ABCL in Q1 2021 and held it in 17 quarters. The position peaked at $24.1M in Q3 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Two Sigma Advisers reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 4,878,000 AbCellera Biologics shares in Q1 2026, an estimated $16.7M.
  • Two Sigma Advisers first reported a position in AbCellera Biologics in Q1 2021 and held it in 17 quarters.
  • Two Sigma Advisers's AbCellera Biologics position peaked at $24.1M in Q3 2025.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.